<DOC>
	<DOCNO>NCT02645981</DOCNO>
	<brief_summary>Donafenib versus sorafenib advance hepatocellular cancer .</brief_summary>
	<brief_title>Efficacy Safety Donafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This phase 3 study donafenib , oral multikinase inhibitor target Raf kinase receptor tyrosine kinase , assess efficacy safety patient wiht advanced hepatocellular carcinoma ( HCC ) .The study randomise , control , multicentre study.The control drug sorafenib ( Nexavar ) .The primary endpoint overall survival .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Above 18 year old ; Patients measurable , histologically clinical proven , inoperable HCC ; Patients wtih measurable lesion prove independent radiology committee ( IRC ) ; ChildPugh ( CP ) score 7 less； Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less ; Patients receive prior systemic treatment HCC ; Life expectancy least 3 month ; Adequate hepatic renal function ; Adequate hematologic function ( platelet count , ≥75×109per liter ; hemoglobin ≥9.0g per deciliter ; neutrophil≥1.5×109per liter , ) ; Prothrombin time international normal . Patients receive operate 3 month ; Patients receive transcatheter arterial chemoembolization（TACE） 4 week ; Patients receive systemic therapy ; Patients prior treatment sorafenib ; Central nervous system ( CNS ) involvement ; Severe milddegree ascitic fluid ; Main portal vein tumor thrombus ; Inferior vena cava tumor thrombus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Donafeinb</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Overall Survival</keyword>
</DOC>